The formation and plasticity of neuronal circuits relies on dynamic activity-dependent gene expression. Although recent work has revealed the identity of important transcriptional regulators and of genes that are transcribed and translated in response to activity, relatively little is known about the cell biological mechanisms by which activity alters the nuclear proteome of neurons to link neuronal stimulation to transcription. Using nucleus-specific proteomic mapping in silenced and stimulated neurons, we uncovered an understudied mechanism of nuclear proteome regulation: activity-dependent proteasome-mediated degradation. We found that the tumor suppressor protein PDCD4 undergoes rapid stimulus-induced degradation in the nucleus of neurons. We demonstrate that degradation of PDCD4 is required for normal activity-dependent transcription and that PDCD4 target genes include those encoding proteins critical for synapse formation, remodeling, and transmission. Our findings highlight the importance of the nuclear proteasome in regulating the activity-dependent nuclear proteome and point to a specific role for PDCD4 as a regulator of activity-dependent transcription in neurons.
Stimulus-induced gene expression allows neurons to adapt their structure and function in response to a dynamically changing external environment (Yap and Greenberg, 2018; Holt et al., 2019; Gallegos et al., 2018). Activity-dependent transcription is critical to neural circuit function, from synapse formation during development (West and Greenberg, 2011; Flavell et al., 2006; Wayman et al., 2006; Polleux et al., 2007; Lin et al., 2008) to synaptic plasticity in the mature brain (Bloodgood et al., 2013; Chen et al., 2017; Ramanan et al., 2005; Tyssowski et al., 2018; Yap and Greenberg, 2018). Neuronal activity can regulate gene expression in the nucleus through chromatin modification and transcriptional regulation and in the cytoplasm through regulation of RNA localization, stability, and translation (Martin and Ephrussi, 2009). The extreme morphological polarity and compartmentalization of neurons pose a cell biological challenge to the activity-dependent regulation of gene expression: how are stimuli received at one site coupled to changes in gene expression within specific subcellular compartments? To produce activity-dependent changes in transcription, signals must be relayed from the site where the signal is received, at the synapse, to the nucleus. To better understand how neuronal activity is coupled with changes in transcription, we developed an assay to systematically identify activity-dependent changes in the nuclear proteome of neurons and thereby elucidate novel mechanisms by which neuronal activity alters the concentration of specific proteins in the nucleus. To our knowledge, this study provides the first activity-dependent characterization of the nuclear proteome of neurons.
Neuronal activity can change the concentration of nuclear proteins via a variety of mechanisms, from nucleocytoplasmic shuttling of signaling proteins to synthesis and degradation of nuclear proteins (Ch’ng et al., 2012; Dieterich et al., 2008; Ma et al., 2014; Lin et al., 2008; Bayraktar et al., 2020; Upadhya et al., 2004). Although the activity-dependent transcriptome and translatome of neurons have been extensively characterized (Brigidi et al., 2019; Chen et al., 2017; Dörrbaum et al., 2020; Fernandez-Albert et al., 2019; Hrvatin et al., 2018; Lacar et al., 2016; Tyssowski et al., 2018), less work has been focused on the upstream changes that occur in the nucleus, specifically identifying the population of proteins that undergo activity-dependent changes in nuclear abundance due to regulated transport or stability, which can in turn influence transcription. In this study, we used nucleus-specific proteomic mapping to identify preexisting proteins that undergo activity-dependent changes in concentration in the nucleus. By characterizing stimulus-induced changes in the nuclear proteome, these data provide insight into how activity-dependent transcription is regulated.
Through our screen of nuclear proteins with activity-dependent changes in abundance, we discovered that programmed cell death 4 (PDCD4) undergoes a significant reduction in nuclear concentration following neuronal stimulation. PDCD4 has been studied primarily in the context of cancer, where it has been found to function as a tumor suppressor and translational inhibitor in the cytoplasm (Matsuhashi et al., 2019; Wang and Yang, 2018; Yang et al., 2003). These studies have revealed that the abundance of PDCD4 protein is regulated at multiple levels, including via translation (Asangani et al., 2008; Frankel et al., 2008; Ning et al., 2014), proteasome-mediated degradation (Dorrello et al., 2006), and nucleocytoplasmic trafficking (Böhm et al., 2003), with decreases in PDCD4 correlating with invasion, proliferation, and metastasis of many types of cancer (Allgayer, 2010; Chen et al., 2003; Wang and Yang, 2018; Wei et al., 2012).
Despite being expressed at significant levels in the brain, especially in the hippocampus and cortex (Lein et al., 2007; Li et al., 2021), few studies have addressed the role of PDCD4 in the nervous system. PDCD4 expression in neurons is altered by injury and stress (Jiang et al., 2017; Narasimhan et al., 2013; Li et al., 2021), and recent work has shown that, as in cancer cells, PDCD4 may act as a translational repressor in neurons (Li et al., 2021; Di Paolo et al., 2020). However, the impact of neuronal activity on PDCD4 concentration and the function of nuclear, as opposed to cytoplasmic, PDCD4 remains unknown. Here, we show that neuronal activity stimulates PKC- and proteasome-mediated degradation of PDCD4 in the nucleus of neurons and that PDCD4 degradation is necessary for activity-dependent transcription.
In this study, we describe an assay that represents the first, to our knowledge, to identify activity-dependent changes in the nuclear proteome of neurons, and it does so in a manner that is independent of translation. Our results not only elucidate a novel mechanism by which activity can regulate the nuclear proteome but also support a role for the tumor suppressor protein PDCD4 during activity-dependent transcription in neurons.
Identification of the nuclear proteome from silenced and stimulated neurons using APEX2 proximity biotinylation and mass spectrometry (MS)
To identify proteins that undergo activity-dependent changes in nuclear localization or abundance, we analyzed the nuclear proteomes of silenced and stimulated cultured rat forebrain neurons. In developing this assay, we used cAMP-response element binding protein–regulated transcriptional coactivator 1 (CRTC1) as a positive control because we have previously shown that glutamatergic activity drives the synapse-to-nucleus import of CRTC1 and that neuronal silencing decreases CRTC1 nuclear abundance (Ch’ng et al., 2012, 2015). We initially used nuclear fractionation to capture the nuclear proteins but discovered that CRTC1 leaked out of the nucleus during the assay. This suggested that nuclear fractionation was not a suitable method and led us to instead use ascorbate peroxidase 2 (APEX2) proximity biotinylation (Hung et al., 2016), an in situ proximity ligation assay, to identify activity-dependent changes in the nuclear proteome. To specifically label the nuclear proteome, we fused APEX2 to two SV40 NLSs (Kalderon et al., 1984; Fig. 1 A). APEX2 proximity ligation was advantageous for these experiments for the following reasons: (1) APEX2 biotinylated proteins can be captured directly by streptavidin pulldown, avoiding the need for subcellular fractionation; (2) biotinylation occurs rapidly (1-min labeling period); and (3) APEX2 can be expressed in a specific cell type of interest. We designed a neuron-specific nuclear-localized APEX2 construct (Fig. 1 A) and transduced cultured rat forebrain neurons with adeno-associated virus (AAV) expressing APEX2-NLS. Immunofluorescence of transduced neurons revealed that APEX2-NLS was expressed specifically in the nucleus (Fig. 1 B). We optimized the MOI of AAV to achieve high transduction efficiency without overexpression of the construct (important because higher doses of AAV led to APEX2-NLS expression in the cytoplasm). When all three components of the labeling reaction were supplied (APEX2-NLS, biotin-phenol, and H2O2), proteins were biotinylated specifically in neuronal nuclei (Fig. 1 B). No labeling was detected in the absence of APEX2-NLS, biotin-phenol, or H2O2.
To identify proteins that undergo activity-dependent changes in nuclear abundance, we silenced neurons for 1 h with the voltage-gated sodium channel antagonist tetrodotoxin (TTX) or stimulated neurons for 1 h with bicuculline (Bic), which inhibits GABAA receptors and drives glutamatergic transmission. We also inhibited protein synthesis using cycloheximide (CHX) in these experiments because many of the genes that are rapidly transcribed and translated in response to activity encode nuclear proteins (Yap and Greenberg, 2018; Heinz and Bloodgood, 2020; Alberini, 2009). We were concerned that the translation of activity-dependent genes would overshadow, and thereby hinder the detection of, the upstream changes that occur in the nuclear proteome resulting from alterations in nuclear protein localization or stability. We confirmed that the CHX treatment used throughout this study impairs protein translation, as detected by the strong reduction of new protein synthesis using L-azidohomoalanine (AHA) labeling (Fig. S1, A and B) as well as the complete inhibition of activity-dependent FOS induction (Fig. S1, C and D).
After the neurons were silenced or stimulated for 1 h and the 1-min labeling reaction was performed (Fig. 1 C), protein lysates were collected for analysis by Western blotting and MS. In neurons expressing APEX2-NLS, many proteins at a variety of molecular weights were biotinylated in both TTX and Bic conditions, whereas very few proteins were biotinylated in the no-APEX control, as detected by Western blot analysis (Fig. 1 D). The bands detected in the no-APEX control were at molecular weights of known endogenously biotinylated proteins (Hung et al., 2016). For all experiments, we also confirmed by immunocytochemistry (ICC) that the APEX2-NLS construct was localized to the nucleus during both experimental conditions (Fig. S1, E and F). For MS, biotinylated proteins were captured using streptavidin pulldown, and the nuclear proteomes were characterized using the tandem mass tag–MS/MS/MS–synchronous precursor selection (TMT-MS3-SPS) acquisition method (Ting et al., 2011) through liquid chromatography–MS. We detected 4,407 proteins, and, of those, 2,860 proteins were significantly enriched above the no-APEX negative control with log2 fold change (FC) >3 and adjusted P value <0.05 (Table S1). To assess nuclear enrichment of the samples, we performed gene ontology (GO) cellular component analysis on the list of 2,860 proteins that were enriched above no-APEX (which could be matched to 2,615 unique gene identifiers). Approximately 80% of the top 100 most abundant proteins detected in the study contained the GO term “nucleus,” and >60% of the entire list of 2,615 proteins contained the GO term nucleus (Fig. S1 G). We performed GO cellular component enrichment analysis and found that most of the top enriched terms were components of the nucleus (Fig. S1 H and Table S2).
When comparing the Bic and TTX conditions, 23 proteins were differentially expressed in the nucleus with log2 FC >0.5 or log2 FC less than −0.5 and P value <0.05 (Table S1). The highest-ranked protein by log2 FC enriched in the Bic versus TTX nuclear proteome was the synapse-to-nucleus signaling protein, CRTC1 (Ch’ng et al., 2015; Nonaka et al., 2014; Ch’ng et al., 2012; Sekeres et al., 2012; Fig. 1 E). The highest-ranked proteins enriched in the TTX versus Bic nuclear proteome were histone deacetylase 4 (HDAC4) and HDAC5, both of which have been reported to undergo nuclear export following neuronal stimulation (Chawla et al., 2003; Schlumm et al., 2013; Fig. 1 F). Using ICC, we confirmed that CRTC1 increased in the nucleus and HDAC4 decreased in the nucleus following Bic stimulation (Fig. 1, G–J). These findings demonstrate that the nucleus-specific APEX2 proximity ligation assay successfully captured activity-dependent changes in the nuclear proteome of neurons.
Neuronal stimulation decreases PDCD4 protein concentration in the nucleus and cytoplasm of neurons
Among the proteins that underwent activity-dependent changes in nuclear concentration, the PDCD4 protein was significantly enriched in the TTX-treated nuclear proteome compared with the Bic-treated nuclear proteome. To validate this finding, we characterized the expression of PDCD4 protein in cultured neurons using ICC, and found that PDCD4 was present in both the nucleus and cytoplasm of neurons (Fig. 2 A and Fig. S2 A). Bic stimulation significantly decreased PDCD4 protein expression in the nucleus by ∼50% (Fig. 2, A and B), with a smaller decrease of ∼20% in the cytoplasm (Fig. 2 C). The decrease of PDCD4 occurred within 15 min of Bic stimulation, and PDCD4 protein levels continued to decrease further with longer incubations of Bic up to 3 h (Fig. 2 D). After washout of a 1-h Bic stimulation, PDCD4 protein expression gradually returned toward baseline levels, although PDCD4 protein concentration was still below baseline 24 h after washout (Fig. 2 E).
In complementary experiments, we transduced neurons with AAV expressing C-terminal HA-tagged PDCD4 (Fig. S2 B) and characterized PDCD4-HA expression by Western blot analysis (Fig. 2 F) and ICC (Fig. S2, C and D). By Western blot analysis, we found that total PDCD4-HA protein levels decreased by ∼50% following Bic stimulation (Fig. 2 F). By ICC, both nuclear and cytoplasmic PDCD4-HA decreased by ∼40% (Fig. S2, C and D). To further validate the Bic-induced decrease in PDCD4, we also created an N-terminal V5-tagged PDCD4 plasmid (Fig. S2 B) and transfected the construct in neurons. Consistent with the results from endogenous PDCD4 and transduced C-terminally HA-tagged PDCD4, both nuclear and cytoplasmic V5-PDCD4 decreased by ∼40% with Bic stimulation (Fig. S2, E and F). These results show that exogenously expressed PDCD4 concentration in neurons is regulated by activity and that the decrease in PDCD4 represents a decrease in the protein rather than cleavage into multiple fragments.
We also found that depolarization of neurons with 40 mM KCl for 5 min significantly decreased PDCD4 protein concentration by ∼40% in the nucleus (Fig. 2 G) and ∼30% in the cytoplasm (Fig. 2 H), as detected immediately after the 5-min treatment. Altogether, these results indicate that increases in glutamatergic transmission and depolarization lead to a rapid and long-lasting reduction in PDCD4 abundance in the nucleus and, to a lesser extent, the cytoplasm of neurons.
PDCD4 undergoes proteasome-mediated degradation following neuronal stimulation
In nonneuronal cells, PDCD4 has been reported to undergo miRNA-mediated translational repression (Asangani et al., 2008; Frankel et al., 2008; Ning et al., 2014), stimulus-induced nuclear export (Böhm et al., 2003), and stimulus-induced proteasome-mediated degradation (Dorrello et al., 2006). We sought to investigate the mechanisms of the neuronal activity-dependent decrease of PDCD4 (Fig. 3 and Fig. S3). Because the assay we used to detect activity-dependent changes in the nuclear proteome was conducted in the presence of the protein synthesis inhibitor CHX, we considered it unlikely that the Bic-induced decrease in PDCD4 was due to miRNA-mediated translational repression. To confirm this, we conducted PDCD4 ICC of TTX-silenced and Bic-stimulated neurons in the presence or absence of CHX and found that CHX did not block the Bic-induced decrease in PDCD4 (Fig. S3, A and B), thereby ruling out a role for activity-dependent miRNA-mediated translational regulation.
To investigate the mechanism underlying the decrease in nuclear PDCD4, we tested if the decrease in nuclear abundance was due to activity-dependent increases in nuclear export. Nuclear export of PDCD4 is mediated by the nuclear export protein, CRM1, and sensitive to the nuclear export inhibitor, leptomycin B (LMB; Böhm et al., 2003). Long incubation with LMB successfully caused nuclear accumulation of PDCD4 in unstimulated neurons (Fig. S3 C); however, LMB was unable to prevent the activity-dependent decrease of nuclear PDCD4 following stimulation (Fig. 3 A and Fig. S3 D). This result demonstrates that regulated nuclear export is not required for the activity-dependent decrease of PDCD4.
We next hypothesized that regulated ubiquitin proteasome-mediated degradation may explain the Bic-induced decrease of PDCD4. To test this idea, we incubated TTX-silenced and Bic-stimulated neurons with the proteasome inhibitors epoxomicin (Epox) or bortezomib (Bort). The proteasome inhibitors impaired Bic-induced decreases of PDCD4 in both the nucleus and cytoplasm of neurons (Fig. 3, B and C; and Fig. S3, E and F), indicating that neuronal activity decreases PDCD4 concentrations via proteasome-mediated degradation. The finding that the nuclear export inhibitor LMB did not block the Bic-induced decrease of PDCD4 in the nucleus (Fig. 3 A) indicates that activity regulates proteasome-mediated degradation of nuclear PDCD4 directly in the nucleus, rather than by nuclear export of PDCD4 followed by degradation in the cytoplasm.
The E3 ubiquitin ligases β-transducin repeat-containing protein 1/2 (βTRCP1/2) have been shown to be required for the proteasome-mediated degradation of PDCD4 in the T98G glioblastoma cell line (Dorrello et al., 2006). βTRCP1/2 belong to the family of Cullin-RING E3 ubiquitin ligases, which require neddylation in order to be activated (Merlet et al., 2009). To determine if this family of ligases is involved in the activity-dependent decrease of PDCD4 in neurons, we used the neddylation inhibitor MLN4924 (MLN) and found that it blocked the Bic-induced decrease of PDCD4 in the nucleus (Fig. 3 D) and cytoplasm (Fig. S3 G) of neurons. This result further supports the finding that PDCD4 undergoes proteasome-mediated degradation following Bic stimulation, likely through ubiquitination by βTRCP1/2.
PDCD4 S71A mutation and PKC inhibition prevent the activity-dependent decrease of PDCD4
To understand how neuronal activity at synapses leads to proteasome-mediated degradation of PDCD4 in the nucleus, we focused on PDCD4’s βTRCP-binding motif. Previous work in T98G glioblastoma cells has shown that phosphorylation of Ser67, Ser71, and/or Ser76 in the βTRCP-binding region of PDCD4 is necessary for βTRCP binding and subsequent proteasome-mediated degradation of PDCD4 (Dorrello et al., 2006). To test if a mutation in PDCD4 at one of these sites would prevent the activity-dependent decrease of PDCD4 in neurons, we expressed WT and mutant (S71A) PDCD4-HA in cultured neurons using AAV (Fig. 4, A and B). Similar to endogenous PDCD4, we found that WT PDCD4-HA decreased following Bic stimulation, with an ∼30% decrease in nuclear HA intensity and an ∼15% decrease in cytoplasmic intensity, as detected by ICC (Fig. 4 C and Fig. S3 H). In contrast, the PDCD4-HA S71A mutant did not undergo an activity-dependent decrease in either the nucleus or cytoplasm, but showed a slight activity-dependent increase in nuclear intensity (Fig. 4 C). In complementary experiments, we found that Bic stimulation resulted in an ∼40% decrease of WT PDCD4-HA signal by Western blot analysis, whereas PDCD4-HA S71A did not decrease after stimulation (Fig. 4 D). These results suggest that phosphorylation of S71 in PDCD4’s βTRCP-binding motif is necessary for its activity-dependent degradation in neurons.
The βTRCP-binding region in PDCD4 contains canonical phosphorylation consensus sites for the kinases S6K1 and PKC (Fig. 4 B); Ser71 is a consensus site for PKC, and Ser67 and Ser76 are consensus sites for S6K1 (Dorrello et al., 2006; Matsuhashi et al., 2014, 2019; Nakashima et al., 2010). To test which kinase phosphorylates PDCD4 with neuronal activity, we incubated cultures in the S6K inhibitor LY2584702 or the PKC inhibitor Ro-31-8425. We found that the S6K inhibitor LY2584702 did not prevent the Bic-induced decrease of PDCD4 (Fig. 4 E and Fig. S3 I), despite its ability to potently inhibit the phosphorylation of a known S6K target, ribosomal protein S6 (Fig. S3 J). In contrast, the pan-PKC inhibitor Ro-31-8425 completely prevented the activity-dependent decrease (and slightly increased nuclear intensity) of PDCD4 (Fig. 4 F and Fig. S3 K). These results suggest that in response to glutamatergic activity, PKC phosphorylates PDCD4 at Ser71, which enables the ubiquitin ligase βTRCP1/2 to bind and promote the proteasome-mediated degradation of PDCD4.
Stimulus-induced degradation of PDCD4 regulates the expression of neuronal activity-dependent genes
The finding that synaptic activity dynamically regulates PDCD4 protein concentration in the nucleus in response to synaptic activity points to a nuclear function for PDCD4 in coupling neuronal activity with changes in transcription. To investigate a role for PDCD4 in the regulation of activity-dependent transcription, we performed RNA sequencing (RNA-seq) of forebrain cultures transduced with either WT PDCD4 or degradation-resistant PDCD4 (S71A) following neuronal silencing with TTX or stimulation with Bic for 1 h (Fig. 5 and Table S3). Given that PDCD4 has a well-known role in regulating translation, we sought to distinguish between direct PDCD4-mediated transcriptional changes in the nucleus and the changes in expression that are downstream of PDCD4-mediated translational changes in the cytoplasm by performing the experiments in either the presence or absence of CHX. We detected robust Bic-induced increases in normalized read counts of transcripts for canonical immediate early genes such as Npas4, Rgs2, and Egr4 in all biological replicates (WT Bic versus TTX: Npas4 log2 FC = 6.5; Rgs2 log2 FC = 2.4; Egr4 log2 FC = 3.1; Fig. 5 A and Table S3). We identified 912 activity-dependent genes, defined as genes with significant differential expression between Bic and TTX for PDCD4 WT samples (459 up-regulated, 453 down-regulated; adjusted P value <0.05 for WT no CHX; Fig. 5, B–D). Clustering of activity-dependent genes by FC across sample types revealed that most activity-dependent genes showed similar FCs between PDCD4 WT and PDCD4 S71A samples (Fig. 5 B), especially for genes with relatively high activity-dependent FCs (Fig. 5 C). However, Fig. 5 B also shows that PDCD4 S71A altered activity-dependent changes in gene expression for a subset of genes. Specifically, we found that PDCD4 S71A led to a decrease in activity-induced differential expression for a substantial proportion of genes: 43% of activity-dependent up-regulated genes (198 genes) and 57% of activity-dependent down-regulated genes (260 genes) were not significantly up-regulated or down-regulated, respectively, in the PDCD4 S71A samples (Fig. 5 D). These results suggest that regulated degradation of PDCD4 is important for the expression of activity-dependent genes in neurons.
This inhibition of activity-dependent gene expression could be due to both a potential role for PDCD4 in transcriptional processes and secondary effects from PDCD4’s regulation of translation of specific transcripts (Matsuhashi et al., 2019; Wang and Yang, 2018). To isolate effects at the transcription level, we focused on CHX-insensitive activity-dependent genes, that is, genes that showed activity-dependent differential expression in both the presence and absence of CHX (in WT, 459 genes after excluding 3 genes that showed differential expression in different directions with or without CHX; Fig. 6). We ranked CHX-insensitive genes by their change in activity-dependent FC between PDCD4 WT and PDCD4 S71A samples and identified 91 putative PDCD4 target genes that showed large differences in activity-dependent gene expression between WT and degradation-resistant PDCD4 samples (see Materials and methods; Fig. 6 A). We validated the effect of PDCD4 on activity-dependent gene expression with quantitative RT-PCR (RT-qPCR) for two of the genes with the largest change between PDCD4 WT and PDCD4 S71A (Scd1 and Thrsp; Fig. S4 A). To confirm a role for PDCD4 in regulating gene expression, we tested the effect of PDCD4 knockdown and overexpression on the transcript abundance of these putative PDCD4 target genes. We found that PDCD4 siRNA knockdown of endogenous PDCD4 significantly up-regulated the expression of Scd1 and Thrsp (Fig. S4 B), demonstrating that endogenous PDCD4 represses the expression of these target genes. Overexpression of PDCD4 using PDCD4 AAV had a smaller effect on the target genes, significantly down-regulating Thrsp but only slightly and nonsignificantly down-regulating Scd1 (Fig. S4 C). These findings support a role for PDCD4 in gene expression regulation and demonstrate that endogenous levels of PDCD4 are sufficient to repress the expression of target genes.
We performed motif analysis of promoter sequences of the putative PDCD4 target genes and found motifs similar to those in promoters of other CHX-insensitive activity-dependent genes (e.g., AP-1/TRE, ATF/CRE, Sp1/Klf motifs; Fig. S5), suggesting that there was not a specific transcription factor motif associated with putative PDCD4 target genes. GO analysis of the putative PDCD4 target genes showed enrichment for neuronal signaling terms, such as “nervous system development” (GO:0007399; 28 genes; false discovery rate [FDR] = 9.28E-04) and “synapse” (GO:0045202; 18 genes; FDR = 6.54E-03), whereas, for comparison, other CHX-insensitive activity-dependent genes showed enrichment for terms related to transcription, such as “regulation of gene expression” (GO:0010468; 169 genes; FDR = 3.11E-25) and “nuclear chromosome” (GO:0000228; 51 genes; FDR = 2.88E-09; Fig. 6 B and Table S4). Putative PDCD4 targets included genes encoding proteins critical for synapse formation, remodeling, and transmission such as Shank1, p35, Abhd17b, Gap43, cofilin, spectrin-β2, myosin-Va, dendrin, Jacob, SNAP-β, voltage-dependent calcium channel-α2/δ1, α-tubulin, and β-actin (Fig. 6 C). Together, these results suggest that PDCD4 functions in the nucleus to regulate the expression of a subset of genes and that inhibiting the stimulation-induced degradation of nuclear PDCD4 results in suppression of the transcription of many activity-dependent genes important for neuronal synaptic function (Fig. 7).
In this study, we sought to test how neuronal activity at the synapse changes the nuclear proteome to regulate activity-dependent transcription. While advances in transcriptomic technologies have enabled the identification of genes that undergo activity-dependent changes in expression (Brigidi et al., 2019; Chen et al., 2017; Fernandez-Albert et al., 2019; Tyssowski et al., 2018), the systematic identification of proteins that undergo changes in subcellular localization and/or stability has been more challenging. We implemented a new proximity ligation approach to characterize changes in the nuclear proteome triggered by neuronal stimulation. Our results provide the first, to our knowledge, unbiased characterization of the population of proteins that undergo changes in nuclear abundance following neuronal silencing and/or glutamatergic stimulation, and they do so in a manner that is independent of translation or transcription. We detected activity-dependent changes in the known nucleocytoplasmic shuttling proteins, CRTC1 and HDAC4/5 (Ch’ng et al., 2012; Chawla et al., 2003), demonstrating the validity of this neuron-specific, subcellular compartment–specific assay. In addition, our results highlight an understudied mechanism of transcriptional regulation in neurons: activity-dependent nuclear proteasome-mediated degradation.
We found that synaptic activity led to proteasome-mediated degradation of the tumor suppressor protein PDCD4 in the nucleus and, to a lesser extent, in the cytoplasm. Given that the nuclear export inhibitor LMB did not block the activity-dependent decrease of nuclear PDCD4, we demonstrated that nuclear PDCD4 is degraded without leaving the nucleus. Many examples of activity-dependent degradation of proteins within the cytoplasm have been reported in neurons (Hegde et al., 1993; Banerjee et al., 2009; Jarome et al., 2011), but fewer cases of activity-dependent degradation of proteins within the nucleus have been described (Upadhya et al., 2004; Bayraktar et al., 2020; Kravchick et al., 2016). Nonetheless, the nucleus contains machinery for proteasome-mediated degradation, and there are numerous examples of proteins that are degraded by the nuclear proteasome in nonneuronal cells, including transcriptional regulators and cell-cycle proteins (von Mikecz, 2006). Neuronal nuclei have also been shown to contain machinery for proteasome-mediated degradation (Mengual et al., 1996) and exhibit proteasomal activity, albeit with less activity than is present in the cytoplasm (Upadhya et al., 2006; Tydlacka et al., 2008). Activity-dependent nuclear proteasome–mediated degradation of transcriptional regulators represents an important mechanism by which synaptic activity regulates gene expression.
In neurons, synaptic activity leads to an increase in the activity of many kinases, including S6K and PKC (Callender and Newton, 2017; Biever et al., 2015). We found that a phospho-incompetent serine-to-alanine mutation at Ser71 prevented the activity-dependent degradation of PDCD4 and that phosphorylation by PKC, but not S6K, was required for this activity-dependent degradation. This result is consistent with previous studies in other cell types, demonstrating that either S6K or PKC is required for PDCD4 phosphorylation, depending on the signaling pathway (Matsuhashi et al., 2019, 2014; Dorrello et al., 2006; Nakashima et al., 2010; Schmid et al., 2008). The stimulus-specific requirement of either S6K or PKC for PDCD4 degradation raises the interesting possibility that different types of neuronal stimulation could trigger PDCD4 degradation via distinct signaling pathways. Supporting this idea, two studies in neurons have suggested that PDCD4 degradation may be regulated by S6K in response to injury and stress (Li et al., 2021; Di Paolo et al., 2020), whereas our study demonstrated that PDCD4 degradation was mediated by PKC. PKC is typically activated at the cell surface (Gould and Newton, 2008); however, it can translocate from the cytoplasm to the nucleus after activation and can be activated directly in the nucleus (Lim et al., 2015; Martelli et al., 2006), where it phosphorylates nuclear targets, including histones and transcription factors (Lim et al., 2015; Martelli et al., 2006).
PDCD4 has been well characterized as a translational repressor in the cytoplasm of cancer cells (Wang et al., 2017; Wedeken et al., 2011; Yang et al., 2004). Low concentrations of PDCD4 have been reported to correlate with invasion, proliferation, and metastasis of many types of cancers (Allgayer, 2010; Chen et al., 2003; Wang and Yang, 2018; Wei et al., 2012). However, the role of PDCD4 in the nucleus is less well characterized, even though the protein is predominantly localized in the nucleus of many cells (Böhm et al., 2003). Despite being highly expressed in neurons, few studies have examined the neuronal function of PDCD4 (Di Paolo et al., 2020; Li et al., 2021; Narasimhan et al., 2013), and, as far as we are aware, no previous study has identified a role for PDCD4 in activity-dependent transcription in neurons. In our study, we detected a larger activity-dependent decrease of PDCD4 in the nucleus than in the cytoplasm, and we found that blocking PDCD4 degradation suppressed activity-dependent gene expression. These findings suggest that the proteasome-mediated degradation of PDCD4 is important for regulating activity-dependent transcription following neuronal stimulation. Previous studies in nonneuronal cells have indicated that PDCD4 can inhibit AP-1–dependent transcription, although it is unclear whether this is a direct role in the nucleus (Bitomsky et al., 2004) or an indirect role regulating the translation of signaling proteins in the cytoplasm (Yang et al., 2006). PDCD4 has also been shown to bind to the transcription factors CSL (Jo et al., 2016) and TWIST1 (Shiota et al., 2009) and inhibit their transcriptional activity. Although activity-dependent degradation of cytoplasmic PDCD4 was weaker and less consistent than that of nuclear PDCD4, we cannot rule out the possibility that PDCD4 has a translation-independent role in the cytoplasm (such as binding to signaling proteins) that could indirectly regulate transcription. However, we propose that PDCD4 has a direct role in regulating activity-dependent transcription in the nucleus, in addition to its well-characterized role as a translational repressor in the cytoplasm.
We identified 91 genes that are putative activity-dependent targets of PDCD4, including genes encoding proteins that are important for synaptic function. The activity-dependent down-regulation of PDCD4 in neurons is reminiscent of the concept of “memory suppressor genes” (Abel and Kandel, 1998), genes that act as inhibitory constraints on activity-dependent neuronal plasticity. By analogy to PDCD4 function during cancer metastases, decreases in PDCD4 in neurons would function to enable experience-dependent neuronal growth and remodeling. Dysregulated PDCD4 concentrations have also been reported to underlie a variety of metabolic disorders, including polycystic ovary syndrome, obesity, diabetes, and atherosclerosis, highlighting the critical role PDCD4 plays in regulating gene expression in multiple cell types (Lu et al., 2020). Our study provides the first transcriptomic profile of PDCD4 that is independent of PDCD4’s role in translation. These results provides insight into the transcriptional targets of PDCD4, which is of relevance not only to neuroscience but also to the study of PDCD4 in cancer.
Taken together, our findings illustrate the utility of proximity ligation assays in identifying activity-dependent changes in the proteome of subcellular neuronal compartments and point to the array of cell biological mechanisms by which activity can regulate the neuronal proteome. They also focus attention on the tumor suppressor protein PDCD4 as a critical regulator of activity-dependent gene expression in neurons, highlighting a role for PDCD4 in regulating the transcription of genes involved in synapse formation, remodeling, and transmission. This new role is in addition to PDCD4’s well-characterized role as a translational inhibitor (Wang and Yang, 2018), and future investigation of the mechanisms by which PDCD4 regulates transcription of these genes will provide further insight into the understudied role of PDCD4 as a transcriptional regulator. Such studies also promise to deepen our understanding of the specific cell and molecular biological mechanisms by which experience alters gene expression in neurons to enable the formation and function of neural circuits.
Materials and methods
Experimental model details
Primary neuronal cultures
All experiments were performed using approaches approved by the University of California, Los Angeles, Animal Research Committee. Forebrains from postnatal day 0 Sprague-Dawley rats (Charles River) were dissected in cold HBSS (Thermo Fisher Scientific) supplemented with 10 mM Hepes buffer and 1 mM sodium pyruvate. Sex was not determined, and tissues from male and female pups were pooled. The tissue was chopped finely and digested in 1× trypsin solution (Thermo Fisher Scientific) in HBSS (supplemented with 120 µg/ml DNase and 1.2 mM CaCl2) for 15 min at 37°C. The tissue was washed and triturated in DMEM (Thermo Fisher Scientific) + 10% FBS (Omega Scientific) before plating on polyDL-lysine (PDLL)-coated (0.1 mg/ml; Sigma) 10-cm dishes or 24-well plates containing acid-etched PDLL-coated coverslips (Carolina Biologicals). Neurons were plated at a density of one forebrain per 10-cm dish (for MS experiments) or one-half forebrain per entire 24-well plate (for ICC, RNA-seq, and Western blot experiments). Neurons were cultured in Neurobasal-A medium (Thermo Fisher Scientific) supplemented with 1× B-27 (Thermo Fisher Scientific), 0.5 mM GlutaMAX (Thermo Fisher Scientific), 25 µM monosodium glutamate (Sigma), and 25 µM β-mercaptoethanol (Sigma) and incubated at 37°C, 5% CO2. When applicable, neurons were transfected with plasmids using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions at day in vitro (DIV) 2, transduced with AAV at DIV 13, or treated with 1 µM control Accell siRNA (D-001910-10-20; Horizon Discovery) or 1 µM PDCD4 Accell siRNA (E-097927-00-0020; Horizon Discovery) at DIV 15. All experiments were performed at DIV 20.
Generation of plasmids and AAV
To create human synapsin promoter (hSyn) NLS-APEX2-EGFP-NLS, APEX2 was amplified from the pcDNA3 APEX2-NES plasmid (gift from Alice Ting, Stanford University, Stanford, CA; Addgene plasmid 49386) with three sequential sets of primers to add SV40 NLS to both the N-terminus and C-terminus of APEX2 (primer sets 1–3; Table S5). The design of using NLS on both sides of APEX2 was based on the design of Cas9-NLS (Swiech et al., 2015). NLS-APEX2-NLS was then inserted into the pAAV-hSyn-EGFP plasmid (gift from Bryan Roth, University of North Carolina, Chapel Hill, NC; Addgene plasmid 50465) between the BamHI and EcoRI sites, replacing the EGFP insert. The final hSyn NLS-APEX2-EGFP-NLS construct was created by amplifying hSyn NLS-APEX2-NLS (primer set 4; Table S5) and EGFP (primer set 5; Table S5) and joining the two products at NheI and SacI.
To create hSyn PDCD4-HA, rat PDCD4 was amplified from cultured neuron cDNA (primer set 6; Table S5) with a C-terminal HA tag and then inserted into the pAAV-hSyn-EGFP plasmid between NcoI and EcoRI, replacing the EGFP insert. The S71A mutation was created using site-directed mutagenesis (services by GENEWIZ) to mutate serine 71 (TCT) to alanine (GCT). The hSyn V5-PDCD4-HA construct was created by adding a V5 tag to the N-terminus of PDCD4-HA using PCR-based mutagenesis (services by GENEWIZ).
AAV9 was generated for APEX2-NLS, PDCD4-HA WT, and PDCD4-HA S71A at the Penn Vector Core.
Neurons were preincubated with CHX (60 µM; Sigma) for 15 min; LMB (10 nM; Sigma) for 30 min; LY2584702 (1 µM; Cayman Chemical) or Ro-31-8425 (5 µM; Sigma) for 1 h; or Epox (5 µM; Enzo Life Sciences), Bort (10 µM; APExBIO), or MLN (50 nM; APExBIO) for 2 h. Inhibitors remained in the media throughout the duration of each respective experiment, incubated at 37°C. For neurons treated with inhibitors dissolved in DMSO (Epox, Bort, MLN, LY2584702, and Ro-31-8425), the final DMSO concentration in the media was 0.1% or less. For neurons treated with LMB, the final methanol concentration in the media was 0.08%. All control groups received an equivalent concentration of vehicle (DMSO or methanol). To silence the neurons, 1 µM TTX (Tocris Bioscience) was applied to the neurons for 1 h. To stimulate the neurons, 40 µM (−)-Bic methiodide (Tocris Bioscience) was applied to the neurons for 1 h unless otherwise stated.
For KCl stimulations, neurons were preincubated with standard Tyrode’s solution (140 mM NaCl, 10 mM Hepes, 5 mM KCl, 3 mM CaCl2, 1 mM MgCl2, and 20 mM glucose, pH 7.4) containing 1 µM TTX for 15 min at RT and then stimulated for 5 min with 40 mM KCl isotonic Tyrode’s solution containing TTX. Control cells remained in the standard Tyrode’s solution containing TTX throughout the experiment.
Control data from LMB (Fig. 3 A and Fig. S3 D) and CHX (Fig. S3, A and B) experiments were combined to generate the data shown in Fig. 2, B and C. Two of the Bort experiments were performed concurrently with two of the MLN experiments, so these experiments partially share control data in Fig. 3, C and D; and Fig. S3, F and G. One of the LY2584702 experiments was performed concurrently with one of the Bort experiments, so Fig. 4 E and Fig. S3 I partially share control data with Fig. 3 C and Fig. S3 F.
APEX2 proximity biotinylation, streptavidin pulldown, and on-bead tryptic digestion
For APEX2 MS experiments, three biological replicates (sets of cultures) were prepared with three samples in each replicate (APEX + Bic, APEX + TTX, and no APEX). Neurons were TTX silenced or Bic stimulated for 1 h in the presence of CHX (as above). During the final 30 min of the treatment, neurons were incubated with 500 µM biotin-phenol (APExBIO) at 37°C. During the final 1 min, labeling was performed by adding H2O2 to a final concentration of 1 mM. To stop the labeling reaction, neurons were washed three times in large volumes of quencher solution (PBS with 10 mM sodium azide, 10 mM sodium ascorbate, and 5 mM Trolox [6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid]).
Neurons were lysed with radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 1% Triton X-100, pH 7.5) containing protease inhibitor cocktail (Sigma), phosphatase inhibitor cocktail (Sigma), and quenchers. Lysates were treated with benzonase (200 U/mg protein; Sigma) for 5 min and then clarified by centrifugation at 15,000 g for 10 min. Samples were concentrated with Amicon centrifugal filter tubes (3K NMWL; Millipore) to at least 1.5 mg/ml protein and quantified using a Pierce 660-nm protein assay kit (Thermo Fisher Scientific).
For each sample, 2 mg lysate was incubated with 220 µl Pierce streptavidin magnetic beads (Thermo Fisher Scientific) for 60 min at RT. Samples were washed twice with RIPA buffer; once with 1 M KCl; once with 0.1 M sodium carbonate; once with 2 M urea, and 10 mM Tris-HCl, pH 8.0; and twice with RIPA buffer according to Hung et al. (2016).
The streptavidin beads bound by biotinylated proteins were then washed three times with 8 M urea and 100 mM Tris-HCl, pH 8.5, and three times with pure water, and then the samples were resuspended in 100 µl 50 mM tetraethylammonium bromide. Samples were reduced and alkylated by sequentially incubating them with 5 mM tris(2-carboxyethyl)phosphine and 10 mM iodoacetamide for 30 min at RT in the dark on a shaker set to 1,000 rpm. The samples were incubated overnight with 0.4 µg Lys-C and 0.8 µg trypsin protease at 37°C on a shaker set to 1,000 rpm. Streptavidin beads were removed from peptide digests, and peptide digests were desalted using Pierce C18 tips (100-µl bead volume), dried, and then reconstituted in water.
The desalted peptide digests were labeled by the TMT10plex Isobaric Label Reagent Set (Thermo Fisher Scientific) according to the manufacturer’s instructions. In brief, peptides were incubated with acetonitrile (ACN)-reconstituted TMT labeling reagent for 1 h and then quenched by adding hydroxylamine. Sample-label matches were no-APEX replicate 1 labeled with TMT126, APEX+Bic replicate 1 labeled with TMT127N, APEX+TTX replicate 1 labeled with TMT127C, APEX+TTX replicate 2 labeled with TMT128N, no-APEX replicate 2 labeled with TMT128C, no-APEX replicate 3 labeled with TMT129N, APEX+Bic replicate 2 labeled with TMT129C, APEX+Bic replicate 3 labeled with TMT130N, and APEX+TTX replicate 3 labeled with TMT130C. Labeled samples were then combined, dried, and reconstituted in 0.1% trifluoroacetic acid for high pH reversed-phase fractionation.
High pH reversed-phase fractionation
High pH reversed-phase fractionation was performed using the Pierce High pH Reversed-Phase Peptide Fractionation Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. In brief, peptides were bound to the resin in the spin column and then eluted by stepwise incubations with 300 µl of increasing ACN concentrations. The eight fractions were combined into four fractions (fractions 1 and 5, 2 and 6, 3 and 7, and 4 and 8). Fractions were then dried by vacuum centrifugation and reconstituted in 5% formic acid for MS analysis.
Liquid chromatography–MS data acquisition
A 75-µm × 25-cm custom-made C18 column was connected to a nanoflow Dionex Ultimate 3000 ultra-high-pressure liquid chromatography system. A 140-min gradient of increasing ACN was delivered at a 200 nl/min flow rate as follows: 1–5.5% ACN phase from minutes 0 to 5, 5.5–27.5% ACN from minutes 5 to 128, 27.5–35% ACN from minutes 128 to 135, 35–80% ACN from minutes 135 to 136, 80% ACN hold from minutes 136 to 138, and then down to 1% ACN from minutes 138 to 140. An Orbitrap Fusion Lumos Tribrid mass spectrometer TMT-MS3-SPS method was used for data acquisition. Full MS scans were acquired at 120K resolution in the Orbitrap device with the automatic gain control target set to 2e5 and a maximum injection time set to 50 ms. MS2 scans were collected in ion trap with turbo scan rate after isolating precursors with an isolation window of 0.7 mass-to-charge ratio and collision-induced dissociation fragmentation using 35% collision energy. MS3 scans were acquired in the Orbitrap spectrometer at 50K resolution, and 10 synchronized selected precursor ions were pooled for each scan using 65% higher-energy C-trap dissociation energy for fragmentation. For data-dependent acquisition, a 3-s cycle time was used to acquire MS/MS spectra corresponding to peptide targets from the preceding full MS scan. Dynamic exclusion was set to 30 s.
MS/MS database search
MS/MS database searching was performed using MaxQuant (22.214.171.124; Cox and Mann, 2008) against the rat reference proteome from the European Molecular Biology Laboratory (UP000002494-10116 RAT, Rattus norvegicus, 21,649 entries). The search included carbamidomethylation as a fixed modification and methionine oxidation and N-terminal acetylation as variable modifications. The digestion mode was set to trypsin and allowed a maximum of two missed cleavages. The precursor mass tolerances were set to 20 and 4.5 ppm for the first and second searches, respectively, whereas a 20-ppm mass tolerance was used for fragment ions. Datasets were filtered at 1% FDR at both the peptide spectrum match and protein levels. Quantification type was set to reporter ion MS3 with 10-plex TMT option.
Statistical inference in MS data
MSStatsTMT (1.4.1; Huang et al., 2020) was used to analyze the MaxQuant TMT-MS3 data in the APEX2 proximity labeling experiment to statistically assess protein enrichment. TTX channels were used for MS run-level normalization. The “msstats” method was then used for protein summarization. P values for t tests were corrected for multiple hypothesis testing using the Benjamini-Hochberg adjustment. We identified proteins that were enriched above the no-APEX negative control using a log2 FC >3 and adjusted P value <0.05 cutoff above the no-APEX condition. Using this protein list, we then identified proteins that were differentially expressed when comparing between Bic and TTX conditions using log2 FC >0.5 or log2 FC less than −0.5 and P value <0.05. It is important to note that we used a nonadjusted P value cutoff when identifying candidate proteins that were differentially expressed between the TTX-silenced and Bic-stimulated conditions, because only HDAC4 and six other proteins had a significant adjusted P value when using these cutoffs. Even CRTC1, a protein that has been shown to undergo activity-dependent changes in multiple studies (Ch’ng et al., 2012, 2015; Nonaka et al., 2014) and confirmed again in the present study, did not reach adjusted P value significance, suggesting that we did not have the statistical power to detect certain activity-dependent changes. Because we used nonadjusted P values to identify candidate proteins, it is especially important to experimentally validate any potential candidate protein.
Protein extraction and Western blot analysis
Neurons were washed in Tyrode’s solution (140 mM NaCl, 10 mM Hepes, 5 mM KCl, 3 mM CaCl2, 1 mM MgCl2, and 20 mM glucose, pH 7.4) and lysed with RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 1% Triton X-100, pH 7.5) containing protease and phosphatase inhibitor cocktails (Sigma). Samples were clarified by centrifugation at 10,000 g for 10 min. Protein concentration was determined using the Pierce bicinchoninic acid protein assay kit (Thermo Fisher Scientific).
Protein lysates were boiled in loading buffer (10% glycerol, 1% SDS, 60 mM Tris-HCl, pH 7.0, 0.1 M DTT, and 0.02% bromophenol blue) for 10 min at 95°C and run on an 8% polyacrylamide gel for 90 min at 120 V. Samples were wet transferred onto a 0.2-µm nitrocellulose membrane for 16 h at 40 mA. The membrane was blocked with Odyssey Blocking Buffer (LI-COR Biosciences) and incubated with the following primary antibodies: mouse HA (901513, 1:1,000; BioLegend), mouse TUJ1 (801201, 1:1,000; BioLegend), mouse S6 (2317, 1:1,000; Cell Signaling Technology), and rabbit phospho-S6 Ser235/236 (4858, 1:2,000; Cell Signaling Technology) for 3–4 h at RT or overnight at 4°C. The membrane was washed with TBS with Tween 20 and incubated with the following secondary antibodies: anti-rabbit IRDye 800CW (1:10,000), anti-mouse IRDye 800CW (1:10,000), anti-mouse IRDye 680CW (1:10,000), and IRDye 800CW streptavidin (1:1,000) for 1 h at RT. The membrane was imaged using the Odyssey infrared imaging system (LI-COR Biosciences). Western blots were quantified using the Image Studio (LI-COR Biosciences) rectangle tool. The relative intensity of each band was calculated by normalizing to a loading control (TUJ1). Within each experiment, all values were normalized to the control (basal) sample.
Neurons were fixed with 4% PFA in PBS for 10 min, permeabilized in 0.1% Triton X-100 in PBS for 5 min, and blocked in 10% goat serum in PBS for 1 h. Neurons were incubated with the following primary antibodies: chicken microtubule-associated protein 2 (MAP2; 1100-MAP2, 1:1,000; PhosphoSolutions), rabbit PDCD4 (9535, 1:600; Cell Signaling Technology), mouse HA (901513, 1:1,000; BioLegend), mouse V5 (R960-25, 1:250; Thermo Fisher Scientific), rabbit CRTC1 (A300-769, 1:1,000; Bethyl Laboratories), rabbit HDAC4 (7628, 1:100; Cell Signaling Technology), and rabbit FOS (2250, 1:500; Cell Signaling Technology) for 3–4 h at RT or overnight at 4°C. Neurons were washed with PBS and incubated at 1:1,000 with the following secondary antibodies: anti-chicken Alexa Fluor 647, anti-rabbit Alexa Fluor 555, anti-mouse Alexa Fluor 555, streptavidin Alexa Fluor 555, and Hoechst 33342 stain for 1 h at RT. Neurons were washed with PBS and mounted on slides with Aqua-Poly/Mount (Polysciences) for confocal imaging.
Protein synthesis assay (AHA labeling)
Neurons were washed once in warm Tyrode’s solution and then incubated in methionine-free Hibernate A (BrainBits) supplemented with 1× B-27 for 30 min at 37°C, 0% CO2 (due to the buffering conditions of Hibernate A). Neurons were then incubated in 4 mM AHA (Thermo Fisher Scientific) or the nonlabeling control 4 mM methionine (Sigma) for 2 h in Hibernate A at 37°C, 0% CO2. When applicable, 60 µm CHX was preincubated for 15 min before the start of the AHA labeling and remained in the media throughout the duration of the experiment. Neurons were washed twice in cold Tyrode’s solution, fixed with 4% PFA in PBS for 10 min, permeabilized in 0.1% Triton X-100 in PBS for 5 min, and washed three times in 3% BSA in PBS. The Click-IT reaction was performed using the Click-iT Cell Reaction Buffer Kit (Thermo Fisher Scientific) and Alexa Fluor 488 alkyne (Thermo Fisher Scientific) according to the manufacturer’s instructions, with a 30-min reaction at RT using 5 µM Alexa Fluor 488 alkyne. Neurons were washed three times in 3% BSA in PBS and then proceeded to the normal ICC protocol above, starting at the goat serum blocking step.
Samples were imaged using a Zeiss LSM 700 confocal microscope with a 40×/1.3 NA oil objective and a 63×/1.4 NA oil objective at RT and 405-nm, 488-nm, 555-nm, and 639-nm lasers, using ZEN microscopy software. All images were acquired using the 40× objective, except for the AHA incorporation protein synthesis experiments, which were imaged using the 63× objective. Identical image acquisition settings were used for all images within an experiment. For each image acquisition, the experimenter viewed the MAP2 and Hoechst channels to select a field of view and was blind to the experimental channel (e.g., HA, PDCD4). For each coverslip, images were taken at multiple regions throughout the coverslip, and two or three coverslips were imaged per condition. Images were collected from at least three experimental replicates (sets of cultures), unless otherwise stated.
ICC images were processed using ImageJ (Schindelin et al., 2012). An ImageJ macro was used to create regions of interest (ROIs) for neuronal nuclei. In brief, the Hoechst signal was used to outline the nucleus, and the MAP2 signal was used to select neurons and exclude nonneuronal cells. To create ROIs for neuronal cytoplasm, the cell body of each neuron was manually outlined using the MAP2 signal, and then the nuclear ROI was subtracted from the total cell body ROI. The ROIs were used to calculate the mean intensity in the channel of interest (e.g., HA, PDCD4) for the nucleus and cytoplasm of each neuron. Within each ICC experimental replicate, the measured values from all ROIs were normalized to the median value of the control condition (basal). For experiments using transfected cells (V5 experiments), the measured intensity of each ROI was normalized to the cotransfection marker (nuclear GFP intensity) in order to normalize for differences in transfection efficiency between cells.
RNA extraction, library preparation, RNA-seq, and data analysis
As above, RNA was extracted from neuronal cultures using the RNeasy Micro Kit (Qiagen). cDNA was synthesized from RNA using the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific) with random hexamers. A no–reverse transcriptase sample was also prepared as a negative control. RT-qPCR was performed on the CFX Connect Real-Time System (Bio-Rad Laboratories) using PowerUp SYBR Green Master Mix (Applied Biosystems). Primer pairs were designed for two housekeeping genes (Hprt, Gapdh), two candidate genes (Scd1, Thrsp), and Pdcd4 using Primer3Plus (Untergasser et al., 2012) and National Center for Biotechnology Information Primer-BLAST (Ye et al., 2012; Table S5). RT-qPCR was performed on six or seven sets of cultures, with technical triplicate reactions for each sample. For each gene, relative quantity was calculated using the formula: EΔCt, where E was calculated from the primer efficiencies (E ≈ 2). Relative gene expression was calculated by normalizing the relative quantity of the gene of interest to the relative quantity of the housekeeping genes Hprt and Gapdh: (E gene)ΔCt gene/GeoMean[(E HPRT)ΔCt HPRT, (E GAPDH)ΔCt GAPDH] (for Fig. S4 A) or Gapdh only (for Fig. S4, B and C; E gene)ΔCt gene/(E GAPDH)ΔCt GAPDH.
Quantification and statistical analysis
For ICC experiments, the quantification of signal intensity is displayed in violin plots created using GraphPad Prism. The medians are indicated with thick lines, and the quartiles are indicated with thin lines. n refers to the number of neurons in each condition, and all individual data points were plotted on the graphs. Our sample sizes were not predetermined. A nonparametric statistical test (Mann-Whitney U test) was used to calculate statistical significance because our data were not normally distributed, as indicated by the violin plots. A Bonferroni correction was used to adjust for multiple hypothesis testing. The sample sizes, statistical tests, medians, and P values are indicated in the figure legends.
For RT-qPCR and Western blot experiments, all data points were displayed using GraphPad Prism, with solid lines indicating the median values. n refers to the biological replicates (sets of cultures), and all data points were plotted on the graphs. The Mann-Whitney U test (Prism) was used to calculate statistical significance. The sample size, statistical tests, medians, and P values are indicated in the figure legends.
Online supplemental material
Fig. S1 accompanies Fig. 1 and provides verification of the protein synthesis inhibitor CHX, examines the nuclear localization of APEX2-NLS, and provides GO analysis results. Fig. S2 accompanies Fig. 2 and provides ICC data of PDCD4 using antibodies against the endogenous protein and epitope-tagged PDCD4. Fig. S3 accompanies Figs. 3 and 4 and provides verification of the nuclear export inhibitor LMB and S6K inhibitor Ly2584702, as well as quantification of cytoplasmic PDCD4. Fig. S4 accompanies Fig. 6 and provides RT-qPCR validation of candidate genes from RNA-seq. Fig. S5 accompanies Fig. 6 and provides motif analysis of promoters of putative PDCD4 target genes. Table S1 contains the MS data from the nuclear proteomes of silenced and stimulated neurons. Table S2 lists the GO analysis of the APEX2-NLS MS. Table S3 contains the RNA-seq data from silenced and stimulated neurons, with PDCD4 WT or S71A. Table S4 lists the GO analysis for putative PDCD4 target genes. Table S5 lists the primer sequences used for cloning and RT-qPCR.
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact author, K.C. Martin (firstname.lastname@example.org). Plasmids generated in this study are available upon request from the lead contact author. This published article includes the MS data generated during this study. The full RNA-seq data are available online (Gene Expression Omnibus accession no. GSE163127).
We thank Sylvia Neumann, Marika Watanabe, and Emilie Marcus for their comments on the manuscript and members of the Martin laboratory for helpful discussion. RNA-seq was performed at the Technology Center for Genomics & Bioinformatics at the University of California, Los Angeles.
This work was supported by National Institutes of Health grant R01MH077022 to K.C. Martin and National Institutes of Health National Research Service Award F31MH113310 to W.A. Herbst.
The authors declare no competing financial interests.
Author contributions: Conceptualization: W.A. Herbst and K.C. Martin. Methodology: W.A. Herbst, W. Deng, J.A. Wohlschlegel, and K.C. Martin. Investigation: W.A. Herbst (APEX2 and PDCD4 neuron experiments), W. Deng (MS), and J.M. Achiro (RNA-seq data analysis). Writing – original draft: W.A. Herbst, J.M. Achiro, and K.C. Martin. Writing – review and editing: W.A. Herbst, J.M. Achiro, and K.C. Martin. Supervision: J.A. Wohlschlegel, J.M. Achiro, and K.C. Martin.